Galectin Therapeutics Unveils Future Plans and Drug Potential
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Buy Rating Affirmed for Galectin Therapeutics Ahead of Phase 2b Interim Analysis and With Strong Cash Position
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Galectin Therapeutics Analyst Ratings
Galectin Therapeutics 2Q Net $12.4M >GALT
Express News | Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
Express News | Galectin Therapeutics Inc- Qtrly Shr Loss $0.20
Express News | Galectin Therapeutics: Believes It Has Sufficient Cash to Fund Planned Operations, Research & Development Activities Through About May 15, 2025
Express News | Galectin Therapeutics: Navigate Trial on Track for Interim Top-Line Analysis in December 2024
Galectin Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Galectin Therapeutics Appoints Khurram Jamil, M.d. to Chief Medical Officer
Press Release: Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
Galectin Therapeutics Inc.'s (NASDAQ:GALT) Largest Shareholders Are Retail Investors With 57% Ownership, Insiders Own 20%
Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
Galectin Therapeutics(GALT.US) Director Buys US$5,949.75 in Common Stock
$Galectin Therapeutics(GALT.US)$ Director FREEMAN KEVIN D purchased 2,500 shares of common stock on Jun 20, 2024 at an average price of $2.3799 for a total value of $5,949.75.Source: Announcement What
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
Galectin Therapeutics Had $23.6M of Cash and Cash Equivalents at March 31 >GALT
Press Release: Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Galectin Therapeutics 4Q Loss/Shr 19c >GALT